{"product_id":"ipamorelin-5mg","title":"Ipamorelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin5mgG.png?v=1779542231\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eIpamorelin 5mg is a synthetic pentapeptide growth hormone secretagogue (GHS) designed for research and laboratory use. Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), stimulating pulsatile growth hormone release from anterior pituitary somatotrophs with high selectivity and minimal effect on cortisol, prolactin, or ACTH — distinguishing it from earlier GHRPs such as GHRP-6. It has been investigated in preclinical models for its effects on GH axis regulation, body composition, bone density, gut motility, and age-related GH decline. It is frequently studied in combination with GHRH analogues such as CJC-1295 to produce synergistic GH pulse amplification. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHS-R1a pharmacology, GH secretion dynamics, and metabolic regulation. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Ipamorelin Concentration: 5mg per vial Peptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular Formula: C₃₈H₄₉N₉O₅ Molecular Weight: 711.85 g\/mol Classification: Selective GHS-R1a agonist (ghrelin receptor agonist) Selectivity: Highly selective for GH secretion; minimal ACTH, cortisol, or prolactin stimulation Purity: ≥98% (HPLC) Form: Lyophilised powder Endotoxin Level: \u0026lt;5 EU\/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Bacteriostatic water Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store in original sealed vial at 2–8°C, away from light and moisture. Stable for 24 months from manufacture date. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 21 days. Do not freeze reconstituted solution. Minimise light exposure. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin: Discovery as the First Selective GH Secretagogue\u003c\/strong\u003e\u003cbr\u003eRaun K, et al. (1998). \u003cem\u003eIpamorelin, the first selective growth hormone secretagogue.\u003c\/em\u003e European Journal of Endocrinology, 139(5), 552–561. \u003ca href=\"https:\/\/doi.org\/10.1530\/eje.0.1390552\"\u003ehttps:\/\/doi.org\/10.1530\/eje.0.1390552\u003c\/a\u003e\u003cbr\u003eThe foundational characterisation study establishing ipamorelin as the first highly selective GH secretagogue, demonstrating potent GH release with minimal effect on ACTH, cortisol, and prolactin in rat models — distinguishing it from GHRP-6 and GHRP-2 and establishing its selectivity profile for GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and GHS-R1a Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eHoward AD, et al. (1996). \u003cem\u003eA receptor in pituitary and hypothalamus that functions in growth hormone release.\u003c\/em\u003e Science, 273(5277), 974–977. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.273.5277.974\"\u003ehttps:\/\/doi.org\/10.1126\/science.273.5277.974\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of GHS-R1a — the primary molecular target of ipamorelin — establishing the receptor biology and signal transduction pathways through which ipamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Postoperative Gut Motility\u003c\/strong\u003e\u003cbr\u003ePoitras P, et al. (2005). \u003cem\u003eIpamorelin, a ghrelin mimetic, stimulates gastrointestinal motility in postoperative ileus in rats.\u003c\/em\u003e Neurogastroenterology \u0026amp; Motility, 17(6), 892–901. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin’s ability to stimulate gastrointestinal motility and accelerate recovery from postoperative ileus in rat models via GHS-R1a activation in the enteric nervous system, expanding its research scope beyond the GH axis into gastrointestinal biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Bone Density in Preclinical Models\u003c\/strong\u003e\u003cbr\u003eSvensson J, et al. (2000). \u003cem\u003eTwo-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.\u003c\/em\u003e (See also: Johansen PB, et al. (1999). \u003cem\u003eIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.\u003c\/em\u003e Growth Hormone \u0026amp; IGF Research, 9(2), 106–113.) \u003ca href=\"https:\/\/doi.org\/10.1054\/ghir.1999.9998\"\u003ehttps:\/\/doi.org\/10.1054\/ghir.1999.9998\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin-induced longitudinal bone growth and increased bone mineral density in rat models via GH\/IGF-1 axis stimulation, providing key preclinical data for researchers investigating GHS-R1a agonism in skeletal biology and bone metabolism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin + CJC-1295 Synergy: Combined GH Secretagogue Research\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eProvides the pharmacodynamic basis for combining GHRH analogues with GHS-R1a agonists such as ipamorelin, demonstrating synergistic amplification of GH pulse amplitude — the key reference for researchers designing combination CJC-1295 + ipamorelin protocols.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248643137879,"sku":"IP5","price":17.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin5mgG.png?v=1779542231","url":"https:\/\/www.mutantpeptides.com\/products\/ipamorelin-5mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}